Routine

Osteoporosis

Endocrine · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Reduced bone mass and microarchitectural deterioration causing fragility fractures. Risk is assessed with clinical tools and DEXA; antiresorptive therapy reduces fracture risk.

Red flags

  • Admit acute hip/vertebral fracture
  • Refer metabolic bone/endocrine: treatment failure (fracture on therapy), very low BMD, premenopausal or male osteoporosis, suspected secondary cause, consideration of teriparatide/romosozumab, complex steroid-induced disease

Assessment

Investigations

  • Assess 10-year fracture risk (FRAX or QFracture), then DEXA for BMD
  • Spine X-ray if vertebral fracture suspected
  • Secondary screen: FBC, ESR, calcium, phosphate, ALP, U&E, LFTs, TSH, vitamin D, PTH, testosterone (men), coeliac serology, myeloma screen if indicated

Management

  • Lifestyle: weight-bearing exercise, stop smoking, limit alcohol, falls prevention, ensure calcium (~1000mg/day) and vitamin D (800-1000 IU/day) intake
  • First-line: oral bisphosphonate (alendronate 70mg weekly or risedronate);
  • IV zoledronate yearly if intolerant
  • Alternatives: denosumab 60mg SC 6-monthly, teriparatide or romososumab for severe/high-risk, HRT/raloxifene in selected women
  • Review need at 3-5 years (drug holiday for bisphosphonates)
  • Co-prescribe bone protection with long-term steroids

Disposition

Admit acute hip/vertebral fracture.

Complications & pitfalls

  • Fragility fractures with morbidity and excess mortality (hip fracture 1-year mortality ~20- 30%), chronic pain, disability, loss of independence
  • Rare therapy risks: osteonecrosis of the jaw, atypical femoral fractures; rebound fractures after stopping denosumab

Exam pearls

  • A fragility fracture is osteoporosis until proven otherwise - treat without waiting for DEXA in the older patient with a hip or vertebral fracture. Never stop denosumab without planned bisphosphonate cover; missed doses cause rapid rebound fractures.
  • Monitoring & follow-up: Reassess fracture risk and consider repeat DEXA after 3-5 years of bisphosphonate (or at drug-holiday review). Check adherence and correct dosing. Do not stop denosumab without transitioning to a bisphosphonate to prevent rebound vertebral fractures. Maintain calcium/vitamin D and falls review.

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.